
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dontinurad
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
Details : Dontinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : Dontinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Phase I
Sponsor : Fortress Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Product Name : Urece
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 29, 2023
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase I
Sponsor : Fortress Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Approved FDF
Recipient : Fuji Yakuhin
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Urece (dotinurad) is a potential best-in-class urate transporter inhibitor that is currently in Phase 1 clinical trial and being developed for the treatment of gout. It can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabso...
Product Name : Urece
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 14, 2022
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Approved FDF
Recipient : Fuji Yakuhin
Deal Size : Undisclosed
Deal Type : Licensing Agreement
